“Non-classical” indication for provocative testing of growth hormone: a retrospective cohort study in adult patients under replacement therapy

Author(s):  
Antonio Mancini ◽  
Carmine Bruno ◽  
Edoardo Vergani ◽  
Alessandro Brunetti ◽  
Gerardo Palmisano ◽  
...  

Background: Adult growth hormone deficiency (GHD) is considered a rare condition. Current guidelines state that GH provocative test is indicated in patients affected by organic hypothalamic/pituitary disease or with history of head injury, irradiation, hemorrhage or hypothalamic disease with multiple pituitary deficiencies. Nevertheless, clinical picture related to GHD may be subtle. Objective: We have retrospectively evaluated the indication to GHRH+arginine test in our monocentric cohort of patients treated with hrGH in order to assess whether other conditions had been considered as a rationale for provocative testing. Methods: 96 patients (51 females and 45 males), aged 19-67 years were included. The GHRH+arginine test had been performed in 29 patients with organic hypothalamic/pituitary disease and in 4 patients for Childhood onset-GHD (Co-GHD). In other patients the diagnosis was suspected for “non classical” reasons in clinical picture suspected for GHD. Results: Classical indications included previously known primary empty sella (n=15), pituitary surgery (n=14), pituitary cyst (n=1), non-secreting pituitary tumors (n=3) but more than half patients (57.3%) had been studied for “non classical” indications: metabolic syndrome (n=25), asthenia (n=13), heart failure (n=4), osteoporosis (n=6), unexplained hypoglycaemia (n=1) and infertility (n=6). The latter represented a significant percentage in the male subgroup under 45 ys. IGF-1 levels were lower than 50th percentile in 63% of patients. Finally, among non-classical reasons organic pituitary disease was discovered in 22 patients. Conclusions: Idiopathic GHD may be unrecognized due to its subtle manifestations and that an extended use of dynamic GH test may reveal such condition. A potential field of investigation could be to identify subsets of patients with clinical conditions caused or worsened by underlying unrecognized GHD.

2017 ◽  
Vol 35 ◽  
pp. 52-56
Author(s):  
Helene M. Markkanen ◽  
Tuula Pekkarinen ◽  
Esa Hämäläinen ◽  
Matti J. Välimäki ◽  
Henrik Alfthan ◽  
...  

2013 ◽  
pp. 4-10
Author(s):  
Giovanni Scanelli ◽  
Luca Catapano ◽  
Beatrice Traverso ◽  
Claudia Aimoni

The Growth Hormone (GH) continues to act lifelong: it has been described, in fact, an Adult Growth Hormone Deficiency (AGHD) syndrome, involving several organs and functions, whose clinical aspects greatly improve with the administration of human recombinant GH. The authors describe, evaluating the most recent data from the literature, the clinical picture, the pathophysiologic mechanisms, the diagnostic tools and the therapy of AGHD.


1999 ◽  
pp. 127-132
Author(s):  
Jens Sandahl Christiansen ◽  
Troels Krarup Hansen ◽  
Steen Nielsen ◽  
Jens Otto Lunde Jörgensen

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Carmine Bruno ◽  
Umberto Basile ◽  
Edoardo Vergani ◽  
Cecilia Napodano ◽  
Gaia Piunno ◽  
...  

Abstract It is known that GH, directly or via IGF-1 activity, influences many aspects of immune response; both humoral and cellular branches are modulated, but no data are available about complement function. CH50 is a screening assay for the activation of the classical complement pathway and it is sensitive to the reduction, absence and/or inactivity of any component of the pathway. The CH50 tests the functional capability of serum complement components of the classical pathway to lyse sheep red blood cells (SRBC) pre-coated with rabbit anti-sheep red blood cell antibody (haemolysin). On the other hand, a low inflammation is present in GH deficiency (GHD) and it is related to cardiovascular risk of such situation, also in partial forms.Therefore, we performed a cohort study in a group of adult GHD patients evaluating CH50 levels to further explore the pattern of inflammatory markers in this condition.We included 17 patients with total GHD (GH peak after stimulation with GHRH+arginine <9 ng/ml with BMI<30 or <4 ng/ml with BMI≥30 Kg/m2; n=15) or partial GHD (peak between 9 and 16 ng/ml with BMI<30 Kg/m2 n=2) with mean±SEM BMI 27.7±2.6 kg/m2 and mean±SEM age 52.5±2.6 ys. The etiology of GHD, assessed by MRI, was: primary empty sella (n=7); post-surgical (n=1) pituitary adenoma (n=4); idiopathic (n=4), pineal cyst (n=1); CH50 has been assayed by turbidimetric method. Mean±SEM CH50 of entire cohort was 50.75±2.5 U/l (normal range 12.5-100 U/ml); however, a significant inverse correlation was observed between GH AUC and CH50 levels (Spearman r=-0.49; p=0.04).This datum joint to our previous observations about increased free light chains of immunoglobulins in GHD, substantiating the hypothesis of chronic low-grade inflammation affecting this condition, which in turn could negatively influence GH secretion. These data could be of interest especially in patients recognized as “idiopathic” GHD, where no pituitary morphologic alterations or anamnestic information (previous surgery, trauma or irradiation) were found. However, these data cannot be conclusive and further studies are needed to establish the causal relationships between these parameters, also in a greater cohort of patients.


Sign in / Sign up

Export Citation Format

Share Document